Outcomes in TN Breast Cancer Predicted by Blood Biomarkers
Biomarkers of residual disease at surgery identify which triple-negative breast cancer patients already treated with neoadjuvant therapy will do well and which will do poorly over the next 2 years. Medscape Medical News …read more